Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
13 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/13/2980661/0/en/Tarsus-Reports-Third-Quarter-and-Year-to-Date-2024-Financial-Results-and-Recent-Business-Achievements.html
13 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/13/2980266/0/en/Tarsus-Welcomes-Kate-Goodrich-M-D-MHS-to-its-Board-of-Directors.html
06 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/06/2976127/0/en/Tarsus-to-Report-Third-Quarter-2024-Financial-Results-on-Wednesday-November-13-2024.html
05 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/05/2974912/0/en/Tarsus-Appoints-Elizabeth-Yeu-M-D-as-Chief-Medical-Officer.html
17 Oct 2024
// FIERCE PHARMA
https://www.fiercepharma.com/marketing/tarsus-taps-actor-betsy-sodaro-embody-mitey-problem-1st-xdemvy-dtc-tv-ad
17 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/17/2964866/0/en/Tarsus-Launches-Your-Mitey-Problem-the-First-Direct-to-Consumer-TV-Campaign-for-XDEMVY-lotilaner-ophthalmic-solution-0-25.html
Details:
Proceeds will be used for the U.S. commercialization of Xdemy (lotilaner), designed to target and kill Demodex mites causing Demodex blepharitis.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: Xdemvy
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $100.0 million
Deal Type : Public Offering
Tarsus Announces Pricing of $100.0 Million Public Offering
Details : Proceeds will be used for the U.S. commercialization of Xdemy (lotilaner), designed to target and kill Demodex mites causing Demodex blepharitis.
Brand Name : Xdemvy
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 29, 2024
Details:
TP-05 (lotilaner) is an oral, well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-Cl channels. It is being evaluated for the prevention of Lyme Disease.
Lead Product(s): Lotilaner
Therapeutic Area: Infections and Infectious Diseases Brand Name: TP-05
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Lead Product(s) : Lotilaner
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tarsus Reports Positive Results from Phase 2a Trial of TP-05 for Lyme Disease Prevention
Details : TP-05 (lotilaner) is an oral, well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-Cl channels. It is being evaluated for the prevention of Lyme Disease.
Brand Name : TP-05
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2024
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel small molecule, approved for Demodex blepharitis under the brand name Xdemvy. Now it is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: TP-03
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel small molecule, approved for Demodex blepharitis under the brand name Xdemvy. Now it is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients w...
Brand Name : TP-03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Details:
The company intends to use the net proceeds to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: Xdemvy
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 01, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $100.0 million
Deal Type : Public Offering
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
Details : The company intends to use the net proceeds to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease...
Brand Name : Xdemvy
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 01, 2023
Details:
The company intends to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease, or MGD, TP-04 and TP-05.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: Xdemvy
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 31, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $100.0 million
Deal Type : Public Offering
Details : The company intends to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease, or MGD, TP-04 and TP-0...
Brand Name : Xdemvy
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2023
Details:
Xdemvy (lotilaner ophthalmic solution), a novel prescription eye drop, is recently approved by FDA and is designed to treat demodex blepharitis by targeting and eradicating the root cause of the disease, demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: Xdemvy
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blephari...
Details : Xdemvy (lotilaner ophthalmic solution), a novel prescription eye drop, is recently approved by FDA and is designed to treat demodex blepharitis by targeting and eradicating the root cause of the disease, demodex mite infestation.
Brand Name : Xdemvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2023
Details:
TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: TP-03
Study Phase: Phase IIIProduct Type: Small molecule
Recipient: LianBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : LianBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.
Brand Name : TP-03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 08, 2023
Details:
TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills ticks that transmit Lyme disease by selectively inhibiting parasite-specific GABA-CI channels.
Lead Product(s): Lotilaner
Therapeutic Area: Infections and Infectious Diseases Brand Name: TP-05
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Lead Product(s) : Lotilaner
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills ticks that transmit Lyme disease by selectively inhibiting parasite-specific GABA-CI channels.
Brand Name : TP-05
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2022
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: TP-03
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Brand Name : TP-03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2022
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Brand Name: TP-03
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Brand Name : TP-03
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?